Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
Proteolysis targeting chimeric molecules (Protacs) target proteins for destruction by exploiting the ubiquitin-dependent proteolytic system of eukaryotic cells. We designed two Protacs that contain the peptide 'degron' from hypoxia-inducible factor-1alpha, which binds to the Von-Hippel-Lindau (VHL) E3 ubiquitin ligase complex, linked to either dihydroxytestosterone that targets the androgen receptor (AR; Protac-A), or linked to estradiol (E2) that targets the estrogen receptor-alpha (ERalpha; Protac-B). We hypothesized that these Protacs would recruit hormone receptors to the VHL E3 ligase complex, resulting in the degradation of receptors, and decreased proliferation of hormone-dependent cell lines. Treatment of estrogen-dependent breast cancer cells with Protac-B induced the degradation of ERalpha in a proteasome-dependent manner. Protac-B inhibited the proliferation of ERalpha-dependent breast cancer cells by inducing G(1) arrest, inhibition of retinoblastoma phosphorylation and decreasing expression of cyclin D1, progesterone receptors A and B. Protac-B treatment did not affect the proliferation of estrogen-independent breast cancer cells that lacked ERalpha expression. Similarly, Protac-A treatment of androgen-dependent prostate cancer cells induced G(1) arrest but did not affect cells that do not express AR. Our results suggest that Protacs specifically inhibit the proliferation of hormone-dependent breast and prostate cancer cells through degradation of the ERalpha and AR, respectively.
Rodriguez-Gonzalez
A
A
Department of Pediatrics, Gwynne Hazen Cherry Laboratories, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1752, USA.
Cyrus
K
K
Salcius
M
M
Kim
K
K
Crews
C M
CM
Deshaies
R J
RJ
Sakamoto
K M
KM
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D013196:Dihydrotestosterone / Q000008:administration & dosage / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods*; D004958:Estradiol / Q000008:administration & dosage / Q000378:metabolism; D047628:Estrogen Receptor alpha / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000008:administration & dosage / Q000737:chemistry; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000187:drug effects; D011944:Receptors, Androgen / Q000187:drug effects / Q000378:metabolism; D011987:Receptors, Steroid / Q000187:drug effects* / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000737:chemistry; D054875:Ubiquitination / Q000502:physiology*
D000970:Antineoplastic Agents; D047628:Estrogen Receptor alpha; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D011944:Receptors, Androgen; D011987:Receptors, Steroid; D011993:Recombinant Fusion Proteins; D013196:Dihydrotestosterone; D004958:Estradiol; D046988:Proteasome Endopeptidase Complex
Cancer Res. 2003 Apr 15;63(8):1981-9
12702592
Proc Natl Acad Sci U S A. 1992 May 1;89(9):4037-41
1570330
J Am Chem Soc. 2004 Mar 31;126(12):3748-54
15038727
J Clin Oncol. 2004 Dec 15;22(24):4991-5004
15611513
Nature. 1996 Nov 7;384(6604 Suppl):23-6
8895597
J Biol Chem. 2002 Mar 1;277(9):7076-85
11751884
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S47-59
16113099
J Steroid Biochem Mol Biol. 1996 Feb;57(3-4):203-13
8645630
J Biol Chem. 1998 Aug 7;273(32):20213-22
9685369
Endocr Relat Cancer. 2005 Sep;12(3):511-32
16172190
Nature. 1996 Nov 7;384(6604 Suppl):17-9
8895595
Mol Endocrinol. 2004 Nov;18(11):2603-15
15284335
EMBO J. 1991 Jul;10(7):1875-83
2050123
Cancer Res. 2007 Jun 1;67(11):5513-21
17545634
J Clin Endocrinol Metab. 1999 May;84(5):1751-3
10323411
Cancer Res. 1996 May 15;56(10):2321-30
8625307
Org Lett. 2003 Sep 18;5(19):3459-62
12967299
Mol Cell. 2003 Mar;11(3):695-707
12667452
Nature. 1996 Nov 7;384(6604 Suppl):11-3
8895593
Endocrinology. 2003 Aug;144(8):3469-76
12865327
Mol Cancer Ther. 2005 Apr;4(4):505-15
15827323
Cancer Gene Ther. 2002 Feb;9(2):117-25
11857028
Cancer Res. 2002 Feb 15;62(4):1008-13
11861374
Cancer Treat Res. 1996;87:263-83
8886457
Br J Cancer. 1999 Sep;81(2):242-51
10496349
Nucleic Acids Res. 1988 Jan 25;16(2):647-63
3340549
Am J Physiol Endocrinol Metab. 2002 Apr;282(4):E891-8
11882509
Cancer Res. 1967 Nov;27(11):1925-30
5624120
J Clin Oncol. 2001 Sep 15;19(18):3808-16
11559718
Mol Cell. 2000 Jun;5(6):939-48
10911988
Clin Cancer Res. 2002 Jul;8(7):2356-61
12114440
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8554-9
11438690
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
15761078
J Biol Chem. 2001 Sep 21;276(38):35684-92
11473106
Cancer Res. 1994 Jun 1;54(11):2861-4
8187068
Endocr Relat Cancer. 2003 Jun;10(2):179-86
12790780
Prostate. 2003 Sep 1;56(4):319-25
12858361
Cancer Res. 1994 Oct 15;54(20):5474-8
7522959
Oncologist. 2003;8(4):335-41
12897330
Cancer Res. 1999 Feb 15;59(4):803-6
10029066
Annu Rev Immunol. 2000;18:621-63
10837071
J Clin Endocrinol Metab. 1992 Sep;75(3):685-9
1517354
J Clin Oncol. 2001 May 1;19(9):2509-16
11331330
Nat Med. 1999 Mar;5(3):280-5
10086382
Mol Cell Proteomics. 2003 Dec;2(12):1350-8
14525958
J Urol. 2000 Jun;163(6):1632-42
10799151
Nature. 1996 Nov 7;384(6604 Suppl):14-6
8895594
Cancer Res. 2001 May 1;61(9):3550-5
11325816
J Urol. 2003 Oct;170(4 Pt 1):1363-9
14501770
Cancer Res. 1999 Jun 1;59(11):2511-5
10363963
Bioorg Med Chem Lett. 2005 Jun 2;15(11):2724-7
15876533